Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 7/2010

01-07-2010 | Original Research Paper

Role of mast cells, stem cell factor and protease-activated receptor-2 in tubulointerstitial lesions in IgA nephropathy

Authors: Hong Liu, Fuyou Liu, Youming Peng, Yinghong Liu, Lingyan Li, Xiwen Tu, Meichu Cheng, Xiangqing Xu, Xing Chen, Guanghui Ling, Lin Sun

Published in: Inflammation Research | Issue 7/2010

Login to get access

Abstract

Background

To elucidate the role of mast cells (MCs) in the pathogenesis of tubulointerstitial lesions in IgA nephropathy (IgAN), we investigated the number of MCs, serum stem cell factor (SCF), protease-activated receptor-2 (PAR-2) and α-smooth-muscle actin (α-SMA) in the kidney and the correlation between MC number, SCF, PAR-2, α-SMA and tubulointerstitial lesions in biopsy specimens and serum creatinine levels, urinary protein excretion in patients with IgA nephropathy.

Methods

Thirty-five patients with IgA nephropathy were enrolled in this study. Clinical parameters, such as serum creatinine and urinary protein excretion, were obtained from each patient at the time of biopsy. Paraffin-embedded sections were used for immunohistochemical staining. Monoclonal antibodies to human tryptase, α-SMA, and SCF and polyclonal antibody to PAR-2 were used as primary antibodies. Ten cortical interstitial fields were randomly selected and assessed using a computer-assisted color image analyzer. Tubulointerstitial fibrosis was assessed as the percentage of the area stained with Masson trichrome in ten cortical interstitial fields.

Results

In all of the control subjects, few tryptase-positive MCs were observed in the glomeruli and interstitium. In contrast, sparse MCs were observed in the interstitium, but not in the glomeruli of diseased kidneys. The number of interstitial MCs in the tubulointerstitial lesions, the expression of SCF, PAR-2 and α-SMA were positively correlated with the degree of interstitial fibrosis. A close correlation between MCs, α-SMA, PAR-2 and SCF was found (r = 0.887 for α-SMA, r = 0.844 for PAR-2, r = 0.853 for SCF, P < 0.01). Also a close correlation between α-SMA, PAR-2 and SCF was found (r = 0.874 for PAR-2, r = 0.862 for SCF, P < 0.01). PAR-2 was correlated with SCF (r = 0.893, P < 0.01). Moreover, a significant positive correlation was observed between the number of interstitial MCs, the expression of SCF, PAR-2 and α-SMA and the serum creatinine level (r = 0.738 for MCs, r = 0.658 for α-SMA, r = 0.692 for PAR-2, r = 0.754 for SCF, P < 0.05).

Conclusions

Our findings suggest that MC infiltration possibly induced by SCF in renal interstitial tissues seems to be associated with tubulointerstitial fibrosis through PAR-2 in IgA nephropathy.
Literature
1.
Berger J, Hinglais N. Intercapillary deposits of IgA–IgG. J Urol Nephrol (Paris). 1968;74:694–5.
2.
D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–27.PubMed
3.
Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503–12.PubMed
4.
Cameron JS. Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol. 1992;6:292–303.CrossRefPubMed
5.
Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20:1–17.PubMed
6.
Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol. 1996;7:2495–508.PubMed
7.
Abe S, Amagasaki Y, Iyori S, Konishi K, Kato E, Sakaguchi H. Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritis patients. Am J Nephrol. 1989;9:30–7.CrossRefPubMed
8.
Roberts ISD, Burrows C, Shanks JH, et al. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol. 1997;50:123–7.CrossRefPubMed
9.
Alexopoulos E, Seron D, Hartley RB, et al. Immune mechanisms in idiopathic membranous nephropathy: the role of interstitial infiltrates. Am J Kidney Dis. 1989;13:404–12.PubMed
10.
Bohle A, Muller GA, Wehrmann M, et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies and chronic interstitial nephritides. Kidney Int. 1996;49:S2–9.
11.
Alpers CE, Hudkins KL, Floege J, et al. Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic injury. J Am Soc Nephrol. 1994;5:201–10.PubMed
12.
Rother MJ, Nowak M, Kerdel FA, et al. The mast cell in health and disease. J Am Acid Dermatol. 1990;23:615–24.CrossRef
13.
Schulman ES. The role of mast cells in inflammatory reponses in the lung. Crit Rev Immunol. 131:35–70.
14.
Craig SS, Deblois G, Schwartz LB. Mast cells in human keloid, small intestine, and lung by an immunoperoxidase technique using a murine monoclonal antibody against tryptase. Am J Pathol. 1986;124:428–35.
15.
Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int. 1998;54:1675–83.CrossRefPubMed
16.
Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis. 1998;32:593–9.CrossRefPubMed
17.
Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol. 2000;53:858–62.CrossRefPubMed
18.
Toth T, Toth-Jakatics R, Jimi S, Ihara M, Urata H, Takebayashi S. Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol. 1999;10:1498–505.PubMed
19.
Galli SJ. New insights into “the riddle of the mast cells”: microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest. 1990;62:5–33.PubMed
20.
Brito JM, Borojevic R. Liver granulomas in schistosomiasis: mast cell dependent induction of SCF expression in hepatic stellate cells is mediated by TNF-α. J Leukoc Biol. 1997;62:389–95.PubMed
21.
Valent P. The riddle of the mast cell: Kit (cd117) ligand as the missing link. Immunol Today. 1994;15:111–4.CrossRefPubMed
22.
Nilsson G, Butterfield JH, Nilsson K, Siegbaha A. Stem cell factor is chemotactic for human mast cells. J Immunol. 1994;1533:3718–23.
23.
Metcalfe DD, Baram D, Mekori YA. Physiol. Physiol Rev. 1997;77:1033–79.PubMed
24.
25.
26.
Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, Laurent GJ, et al. Am J Physiol. 2000;278:L193–201.
27.
Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren S, et al. J Immunol. 1997;158:2310–7.PubMed
28.
Corvera CU, Dery O, McConalogue K, Bohm SK, Khitin LM, Caughey GH, et al. Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. J Clin Invest. 1997;100:1383–93.CrossRefPubMed
29.
Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH, et al. Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol. 1999;8:282–94.PubMed
30.
Schechter NM, Brass LF, Lavker RM, Jensen PJ. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. J Cell Physiol. 1998;176:365–73.CrossRefPubMed
31.
Kawabata A. PAR-2: structure, function and relevance to human diseases of the gastric mucosa. Expert Rev Mol Med. 2002;16:1–17.
32.
Frungieri MB, Weidinger S, Meineke V, Ko¨hn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR-2, COX2, prostaglandins, and PPAR-γ: possible relevance to human fibrotic disorders. Proc Natl Acad Sci USA. 2002;99:15072–7.CrossRefPubMed
33.
Lajoie G, Nadasdy T, Laszik Z, Blick KE, Silva FG. Mast cells in acute cellular rejection of human renal allografts. Mod Pathol. 1996;9:1118–25.PubMed
34.
Hunt LW, Colby TV, Weiler DA, Sur S, Butterfield JH. Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin Proc. 1992;67:941–8.PubMed
35.
Kakizoe E, Shiota N, Tanabe Y, Shimoura K, Kobayashi Y, Okunishi H. Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J Invest Dermatol. 2001;116:118–23.CrossRefPubMed
36.
Bradding P, Feather LH, Wilson S, et al. Immunolocalization of cytokines in the nasal mucosa of normal and perineurial rhinitic subjects: the mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol. 1993;151:3853–65.PubMed
37.
Qu Z, Lieblex JM, Poevers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995;147:564–73.PubMed
38.
Hatamochi A, Fujiwara K, Veki H. Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res. 1985;277:60–4.CrossRefPubMed
39.
Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest. 1991;88:493–9.CrossRefPubMed
40.
Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing fibroblasts. J Clin Biol. 1993;122:1103–11.CrossRef
41.
Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80:2237–45.PubMed
42.
Columbo M, Horowitz EM, Botana LM, McGlashan DW Jr, Bochner BS, Gillis S, et al. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol. 1992;149:599–608.PubMed
43.
Hogaboam C, Kunkel SL, Strieter RM, Taub DD, Lincoln P, Strandiford TJ, et al. Novel role of transmembrane SCF for mast cell activation and eotaxin production in mast cell fibroblast interactions. J Immunol. 1998;160:6166–71.PubMed
44.
El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int. 2001;60:167–72.CrossRefPubMed
45.
46.
Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartmann T, Caughey GH. Tryptase, the dominant secretary granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol. 1995;13:227–36.PubMed
47.
Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells: stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol. 1996;156:257–83.
48.
Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274:C1429–52.PubMed
49.
Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA. 1994;91:9208–12.CrossRefPubMed
50.
Molino M, Woolkalis MJ, Reavey-Cantwell J, Pratico D, Andrade-Gordon P, Barnathan ES, et al. Endothelial cell thrombin receptors and PAR-2: two protease-activated receptors located in a single cellular environment. J Biol Chem. 1997;272:11133–341.CrossRefPubMed
51.
Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells: comparison with the thrombin receptor. J Biol Chem. 1996;271:14910–5.CrossRefPubMed
52.
Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J Clin Invest. 1996;97:1705–14.CrossRefPubMed
53.
Bono F, Lamarche I, Herbert JM. Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2). Biochem Biophys Res Commun. 1997;241:762–4.CrossRefPubMed
54.
Molino M, Raghunath PN, Kuo A, Ahuja M, Hoxie JA, Brass LF. Barnathan ES: differential expression of functional protease activated receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1998;18(5):825–32.PubMed
55.
Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G. Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. FASEB J. 2001;15:1433–5.PubMed
56.
Kawabata A, Kuroda R, Nakaya Y, Kawai K, Nishikawa H, Kawao N. Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. Biochem Biophys Res Commun. 2001;282:432–5.CrossRefPubMed
57.
Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 1997;99:1313–21.CrossRefPubMed
58.
Desmouliere A, Rubbia-Brandt L, Grau G, Gabbiani G. Heparin induces alpha-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab Invest. 1992;67:716–26.PubMed
59.
Ruger BM, Hasan Q, Greenhill NS, Davis PF, Dunbar PR, Neale TJ. Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia. 1996;39:1215–22.CrossRefPubMed
60.
Chihara Y, Ono H, Ishimitsu T, Ono Y, Ishikawa K, Rakugi H, et al. Roles of TGF-beta1 and apoptosis in the progression of glomerulosclerosis in human IgA nephropathy. Clin Nephrol. 2006;65:385–92.PubMed
61.
Ranieri E, Gesualdo L, Grandaliano G, Maiorano E, Schena FP. The role of alpha-smooth muscle actin and platelet derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy. J Nephrol. 2001;14:253–62.PubMed
62.
Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis. 1998;32:593–9.CrossRefPubMed
Metadata
Title
Role of mast cells, stem cell factor and protease-activated receptor-2 in tubulointerstitial lesions in IgA nephropathy
Authors
Hong Liu
Fuyou Liu
Youming Peng
Yinghong Liu
Lingyan Li
Xiwen Tu
Meichu Cheng
Xiangqing Xu
Xing Chen
Guanghui Ling
Lin Sun
Publication date
01-07-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 7/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0159-7

Other articles of this Issue 7/2010

Inflammation Research 7/2010 Go to the issue

Original Research Paper

High-dose antithrombin III prevents heat stroke by attenuating systemic inflammation in rats

Original Research Paper

Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro

Original Research Paper

Prolonged ovalbumin challenge facilitates Th17 polarization in sensitized mice

Original Research Paper

Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population

Original Research Paper

Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus

Erratum

Erratum to: Abstract supplement to the 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits